Mll$^{wt/wt}$


02092003mg.012
DX5 PE
CD3 FITC
02092003mg.013
CD44 PE
CD8 FITC
02092003mg.014
CD4 PE
CD122 FITC
02092003mg.015
CD44 PE
CD43 FITC
02092003mg.016
THY APC
NK1.1 PerCP
02092003mg.016
NK1.1 PerCP
CD45R PE
02092003mg.018
CD11B APC
CD14 FITC
02092003mg.018
CD11B APC
CD8 PerCP
02092003mg.012
NK1.1 PerCP
CD3 FITC
02092003mg.013
CD4 PerCP
CD8 FITC
02092003mg.014
CD8 PerCP
CD122 FITC
02092003mg.015
CD8 PerCP
CD43 FITC
02092003mg.016
CD45R PE
CD3 FITC
02092003mg.017
Sca I PE
C-kit APC
02092003mg.018
CD11B APC
CD14 FITC
02092003mg.018
CD11B APC
CD8 PerCP
02092003mg.012
CD62L APC
CD3 FITC
02092003mg.013
CD62L APC
CD8 FITC
02092003mg.014
CD62L APC
CD122 FITC
02092003mg.015
CD62L APC
CD43 FITC
02092003mg.017
C-kit APC
Sca II FITC
02092003mg.018
Gr-1 PE
CD14 FITC
02092003mg.018
CD8 PerCP
Gr-1 PE
02092003mg.019
Ter PE
CD41 FITC
02092003mg.012
NK1.1 PerCP
DX5 PE
02092003mg.013
CD4 PerCP
CD44 PE
02092003mg.014
CD8 PerCP
CD4 PE
02092003mg.015
CD8 PerCP
CD44 PE
02092003mg.016
CD45R PE
CD3 FITC
02092003mg.018
Gr-1 PE
CD14 FITC
02092003mg.018
CD8 PerCP
Gr-1 PE
02092003mg.019
Ter PE
CD41 FITC
02092003mg.012
CD62L APC
DX5 PE
02092003mg.013
CD62L APC
CD44 PE
02092003mg.014
CD62L APC
CD4 PE
02092003mg.015
CD62L APC
CD44 PE
02092003mg.016
NK1.1 PerCP
CD3 FITC
02092003mg.018
CD8 PerCP
CD14 FITC
02092003mg.018
CD11B APC
Gr-1 PE
02092003mg.020
CD45R PE
CD3 FITC
02092003mg.012
CD62L APC
NK1.1 PerCP
02092003mg.013
CD62L APC
CD4 PerCP
02092003mg.014
CD62L APC
CD8 PerCP
02092003mg.016
THY APC
CD45R PE
02092003mg.016
THY APC
CD3 FITC
02092003mg.020
CD19 APC
CD45R PE
02092003mg.018
CD11B APC
Gr-1 PE
02092003mg.020
NK1.1 PerCP
CD3 FITC

MII$^{ptd/wt}$


02092003mg.032
DX5 PE
CD3 FITC
02092003mg.033
CD44 PE
CD8 FITC
02092003mg.034
CD4 PE
CD122 FITC
02092003mg.035
CD44 PE
CD43 FITC
02092003mg.036
THY APC
NK1.1 PerCP
02092003mg.036
NK1.1 PerCP
CD45R PE
02092003mg.038
CD11B APC
CD14 FITC
02092003mg.038
CD11B APC
CD8 PerCP
02092003mg.032
NK1.1 PerCP
CD3 FITC
02092003mg.033
CD4 PerCP
CD8 FITC
02092003mg.034
CD8 PerCP
CD122 FITC
02092003mg.035
CD8 PerCP
CD43 FITC
02092003mg.036
CD45R PE
CD3 FITC
02092003mg.037
Sca I PE
C-kit APC
02092003mg.038
CD11B APC
CD14 FITC
02092003mg.038
CD11B APC
CD8 PerCP
02092003mg.032
CD62L APC
CD3 FITC
02092003mg.033
CD62L APC
CD8 FITC
02092003mg.034
CD62L APC
CD122 FITC
02092003mg.035
CD62L APC
CD43 FITC
02092003mg.037
C-kit APC
Sca II FITC
02092003mg.038
Gr-1 PE
CD14 FITC
02092003mg.038
CD8 PerCP
Gr-1 PE
02092003mg.039
Ter PE
CD41 FITC
02092003mg.032
NK1.1 PerCP
DX5 PE
02092003mg.033
CD4 PerCP
CD44 PE
02092003mg.034
CD8 PerCP
CD4 PE
02092003mg.035
CD6 PerCP
CD44 PE
02092003mg.036
CD45R PE
CD3 FITC
02092003mg.038
Gr-1 PE
CD14 FITC
02092003mg.038
CD8 PerCP
Gr-1 PE
02092003mg.039
Ter PE
CD41 FITC
02092003mg.032
CD62L APC
DX5 PE
02092003mg.033
CD62L APC
CD44 PE
02092003mg.034
CD62L APC
CD4 PE
02092003mg.035
CD62L APC
CD44 PE
02092003mg.036
NK1.1 PerCP
CD3 FITC
02092003mg.038
CD8 PerCP
CD14 FITC
02092003mg.038
CD11B APC
Gr-1 PE
02092003mg.040
CD45R PE
CD3 FITC
02092003mg.032
CD62L APC
NK1.1 PerCP
02092003mg.033
CD62L APC
CD4 PerCP
02092003mg.034
CD62L APC
CD8 PerCP
02092003mg.036
THY APC
CD45R PE
02092003mg.036
THY APC
CD3 FITC
02092003mg.040
CD19 APC
CD45R PE
02092003mg.038
CD11B APC
Gr-1 PE
02092003mg.040
NK1.1 PerCP
CD3 FITC

Supplemental Fig 1. Representative flow cytometric analyses of BM cells from *Mll*$^{wt/wt}$ and *Mll*$^{ptd/wt}$ mice taken between weeks 12-20, demonstrating no significant differences between these two genotypes. These data are also representative of results obtained in spleen and blood from these two genotypes, with the exception of Ter119 expression in spleen as shown above in Figure 6B and 6C. Staining and analysis were performed on N = 5 mice/genotype as previously described (40).

Supplementary Tables:

Table S.1

	Primers used in *Dorrance et al.*	
	Forward	**Reverse**
Amplicon	**5'⇒3'**	**5'⇒3'**
DNA PCR for PTD	GAGCCTTGGCCCGAATGAAACTGT	CCGGCGAACGTGGCGAGAAA
RT-PCR for PTD	CAGGCCAGAGCAAAGCAAGCA	CCCCAGGGAAGGTAGGAGGTC
HoxA7 Real Time	TTCCGCATCTACCCCTGGAT	CGCAGTCCATCGCCAACTTTA
HoxA9 Real Time	TGAGAGCGGCGGAGACAA	GAGGTCAAGGTCGCAGACCA
HoxA10 Real Time	TGAGAGCGGCGGAGACAA	CGCAGACCACGAAGCAAGCACATT
Hox C8 Real Time	AGCGAAGGACAAGGCCACTT	GGTTCCAGACTATGGCCGACAT
Hox A7 in situ	AACCTGCCCTGCGCCTCCTACGAC	CCTGTGCCTGGCCCTTTACTCCTC
HoxA9 in situ	GCCCGGTGCGCTCTCCTT	TTCATTTTCATCCTGTTCTGG
Hox A10 in situ	AGGCAGCCGGGAAGGAGCGAGTC	AGCAAACAAACACCAAGCAAACAG
Hox A7 External ChIP	CGTCTGTGAGCCTCTTCCCCTTCC	CATTACACCCCCAGATTTACACCA
Hox A7 Internal ChIP	CGGGGGAGGGGGCGAGAT	TTTGTTGTCCGGCAGCTTTCAGTG
Hox A9 External ChIP	GGTCGGTAGCCCATTTTAGGTG	GGGTCCCGCGTGTGAGCA
Hox A10 External ChIP	GCAGCGGGTTGGGCACATTCTCT	AGGGGCAGCAGCTTCTCCAC
Hox A10 Internal ChIP	TGCCCGGCAGCTTCCTTTTC	CTCCCTGGCGGCTTTGACATTGAT
Mll 11-5 real time	GGCCCCCCTCCCAAGTA	AAGAACTGCTCATCCTTGTCCTTT
Mll 14-15 real time	AGTTTTGCCATGTGTGTGGAAG	GTGATAGCTGTTTCGGCACTT

Table S.2

Real Time probe sequences used for *Dorrance et al.*	
Probe Target	**Sequence (5' ⇒ 3')**
Hoxa7	CAGTTCAGGACCCGACAGGAA
Hoxa9	CCCATCGATCCCAATAACCCGG
Hoxa10	AGGGACCCGTCAAGGTTTCCGC
Hoxc8	CCATGGATGAGACCCCACGCTCCT
Mll 11-5	CCCTGTAAAACAAAAAC
Mll 14-15	ACTCCAGCAACTGCTTTGTAG